Kirollos Hanna
Kirollos Hanna
Biomarkers for Response to Anti-PD-1/Anti-PD-L1 Immune Checkpoint Inhibitors: A Large Meta-Analysis [0.03%]
抗PD-1/PD-L1免疫检点抑制剂应答生物标志物的大样本荟萃分析
Arshiya Mariam,Suneel Kamath,Kimberly Schveder et al.
Arshiya Mariam et al.
Background: Immune checkpoint inhibitors (ICIs) that block PD-1/PD-L1 have consistently demonstrated durable clinical activity across multiple histologies but have low overall response rates for many cancers-indicating th...
An Arthroscopic Approach for the Intralesional Curettage of Giant Cell Tumor of the Distal Femur: A Case Report [0.03%]
(distal股骨巨细胞瘤的病灶刮除术的关节镜入路病例报告)
Hans Kristian Nugraha,I Gede Eka Wiratnaya,Putu Astawa
Hans Kristian Nugraha
As a locally aggressive primary benign tumor, giant cell tumor of bone (GCTB) presents a challenge to surgeons, as it often recurs regardless of surgical resection. This report describes a case of GCTB of the distal femur in a man, aged 39 ...
Emerging Strategies to Manage Relapsed and/or Refractory Multiple Myeloma [0.03%]
治疗复发和/或难治多发性骨髓瘤的新型策略
James J Driscoll,James Ignatz-Hoover
James J Driscoll
Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/ Gastroesophageal Adenocarcinoma [0.03%]
循环肿瘤DNA作为预测生物标志物评估曲妥珠单抗失败的HER2阳性胃及胃食管交界腺癌患者使用玛吉妥昔单抗和帕博利尤单抗治疗临床结局的研究
Daniel Vt Catenacci,Yoon-Koo Kang,Hope E Uronis et al.
Daniel Vt Catenacci et al.
Purpose: To assess the ability of circulating tumor DNA (ctDNA)-based testing to identify patients with HER2 (encoded by ERBB2)-positive gastric/gastroesophageal adenocarcinoma (GEA) who progressed on or after trastuzumab...
Zhubin J Gahvari,Natalie S Callander
Zhubin J Gahvari
The treatment of patients with relapsed and refractory multiple myeloma has become increasingly complex due to the rising number of available therapies. Patients are also increasingly exposed to, and refractory to, multiple classes of thera...
Evaluating Treatment Options and the Multidisciplinary Care of Ocular Toxicities of MEK Inhibitors [0.03%]
评估MEK抑制剂的眼毒性多学科治疗方法及选择方案
David L DeRemer,Bently P Doonan
David L DeRemer
Radiation Therapy in Diffuse Large B-Cell Lymphoma: A Little Boost Gets You Over the Finish Line [0.03%]
弥漫性大B细胞淋巴瘤的放疗：一点助力助你冲线
Omran Saifi,Bradford S Hoppe
Omran Saifi
Progressing From Disparity to Equity: Untangling the Complexities of Timely Care and the Rural Cancer Experience [0.03%]
从差异到公平：及时治疗与农村癌症经历的复杂性解构
Richard L Martin,Stephen Schleicher
Richard L Martin
Richard L. Martin III, MD, MPH, and Stephen Schleicher, MD, MBA, share a perspective on rural cancer care.